Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

10x Genomics (TXG) EBITDA (2018 - 2025)

10x Genomics' EBITDA history spans 8 years, with the latest figure at -$19.5 million for Q4 2025.

  • For Q4 2025, EBITDA rose 60.79% year-over-year to -$19.5 million; the TTM value through Dec 2025 reached -$61.0 million, up 68.65%, while the annual FY2025 figure was -$61.0 million, 68.65% up from the prior year.
  • EBITDA for Q4 2025 was -$19.5 million at 10x Genomics, up from -$32.2 million in the prior quarter.
  • Across five years, EBITDA topped out at $30.1 million in Q2 2025 and bottomed at -$94.8 million in Q3 2023.
  • The 5-year median for EBITDA is -$40.7 million (2022), against an average of -$37.3 million.
  • The largest annual shift saw EBITDA tumbled 471.61% in 2022 before it soared 172.18% in 2025.
  • A 5-year view of EBITDA shows it stood at -$18.6 million in 2021, then dropped by 24.03% to -$23.1 million in 2022, then crashed by 138.95% to -$55.2 million in 2023, then rose by 9.69% to -$49.8 million in 2024, then skyrocketed by 60.79% to -$19.5 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's EBITDA are -$19.5 million (Q4 2025), -$32.2 million (Q3 2025), and $30.1 million (Q2 2025).